# A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer

> **NCT04676516** · PHASE2 · COMPLETED · sponsor: **Ottawa Hospital Research Institute** · enrollment: 40 (actual)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** GSK3326595

## Key facts

- **NCT ID:** NCT04676516
- **Lead sponsor:** Ottawa Hospital Research Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-08
- **Primary completion:** 2022-08-15
- **Final completion:** 2022-08-15
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-10-25

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04676516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04676516, "A Phase II Window of Opportunity Trial of PRMT5 Inhibitor, GSK3326595, in Early Stage Breast Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04676516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*